AstraZeneca PLC (LON: AZN)
London
· Delayed Price · Currency is GBP · Price in GBX| Market Cap | 183.09B |
| Revenue (ttm) | 38.88B |
| Net Income (ttm) | 5.10B |
| Shares Out | 1.55B |
| EPS (ttm) | 3.26 |
| PE Ratio | 36.23 |
| Forward PE | 17.67 |
| Dividend | 2.34 (1.99%) |
| Ex-Dividend Date | Aug 8, 2024 |
| Volume | 1,196,413 |
| Open | 11,768 |
| Previous Close | 11,738 |
| Day's Range | 11,695 - 11,846 |
| 52-Week Range | 9,461 - 13,388 |
| Beta | 0.17 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 12, 2024 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus... [Read more]
Financial Performance
In 2023, AstraZeneca's revenue was $45.81 billion, an increase of 3.29% compared to the previous year's $44.35 billion. Earnings were $5.96 billion, an increase of 81.11%.
Financial numbers in USD Financial StatementsNews
Dow Tumbles Over 400 Points; Duckhorn Portfolio Shares Surge
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 150 points on Monday. The Dow traded down 0.97% to 41,940.43 while the NASDAQ fell 0.89% to 17,976.85. T...
Crude Oil Gains Over 3%; Scholar Rock Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 200 points on Monday. The Dow traded down 0.49% to 42,146.78 while the NASDAQ fell 0.36% to 18,073.37. The S...
AstraZeneca Collaborates with CSPC to Develop Innovative Lp(a) Inhibitor
AstraZeneca Collaborates with CSPC to Develop Innovative Lp(a) Inhibitor
AstraZeneca reports positive results for Airsupra v. albuterol study
US Stocks Open Lower; Dow Tumbles Over 150 Points
U.S. stocks traded lower this morning, with the Dow Jones falling more than 150 points on Monday. Following the market opening Monday, the Dow traded down 0.38% to 42,192.55 while the NASDAQ fell 0.29...
AstraZeneca Inks $1.92B License Pact With Hong Kong-Based Firm To Boost Cardiovascular Pipeline
On Monday, AstraZeneca plc (NASDAQ: AZN) entered into an exclusive license agreement with Hong Kong-based CSPC Pharmaceutical Group Ltd to advance the development of an early-stage, novel small-molec...
AIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the BATURA Phase IIIb trial showed AstraZeneca's AIRSUPRA ® (albuterol/budesonide) met the primary endpoint, demonstrating a statist...
Stocks hitting 52-Week Highs: AstraZeneca, eClerx Services, and more
Several companies from the NIFTY 500 index have hit their 52-week highs today, signaling strong performance in the current market. Here’s a closer look at some of the top gainers hitting their peak pr...
AstraZeneca looks to boost cardiovascular pipeline with $2B license deal
AstraZeneca boosts cardiovascular pipeline with exclusive license agreement for YS2302018, a potential treatment for dyslipidaemia.
AstraZeneca to pay up to $2 billion to license cardiovascular drug
AstraZeneca on Monday said it will pay up to $2 billion to license a cardiovascular drug.
AstraZeneca in $1.9 bln licensing deal with HK-listed CSPC
AstraZeneca said on Monday it would pay up to $1.9 billion to CSPC Pharmaceutical Group Ltd in an exclusive license agreement to boost the Anglo-Swedish drugmaker's cardiovascular pipeline.
Avillion announces positive high-level results from Phase III BATURA trial with AstraZeneca's inhaled anti-inflammatory medication Airsupra in asthma patients
London, UK, 7 October 2024 – Avillion Life Sciences Ltd (“Avillion”) announces that the ongoing BATURA Phase IIIb trial evaluating AstraZeneca's Airsupra (albuterol/budesonide) in patients with interm...
Evaluating Eli Lilly Against Peers In Pharmaceuticals Industry
In today's fast-paced and highly competitive business world, it is crucial for investors and industry followers to conduct comprehensive company evaluations. In this article, we will delve into an ext...
Exploring The Competitive Space: Merck & Co Versus Industry Peers In Pharmaceuticals
In the dynamic and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry compar...
AstraZeneca supplemental NDA for Calquence accepted by FDA
CALQUENCE® (acalabrutinib) granted Priority Review in the US for patients with untreated mantle cell lymphoma
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's supplemental New Drug Application (sNDA) for CALQUENCE® (acalabrutinib) has been accepted and granted Priority Review in the US for the treatment of ad...
Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p...
Daiichi Sankyo and AstraZeneca's Enhertu Receives Priority Review from FDA for HER2 Low Breast ...
Daiichi Sankyo and AstraZeneca's Enhertu Receives Priority Review from FDA for HER2 Low Breast Cancer
Owkin Announces Partnership with AstraZeneca to Develop an AI gBRCA Pre-Screen Solution for Breast Cancer
PARIS--(BUSINESS WIRE)--Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics, is pleased to announce a new partnershi...
AstraZeneca's Enhertu application accepted by FDA with priority review
AstraZeneca (AZN) and Daiichi Sanyko (DSKYF)(DSNKY) said the FDA has accepted their application with priority review for expanded approval of Enhertu. Read more here.
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy
Based on DESTINY-Breast06 Phase III trial which demonstrated a statistically significant and clinically meaningful progression-free survival benefit for ENHERTU If approved, AstraZeneca and Daiichi Sa...
Novo's Tough Month Key in Ending Health Stocks' Winning Streak
European health-care stocks are set to snap their longest winning streak since March 2010, dragged down by concerns over Novo Nordisk A/S’s upcoming third-quarter results and experimental drug updates...
Senior Tories cast doubt over Boris Johnson’s plan to ‘invade the Netherlands’
Former prime minister’s claims about wanting to seize Covid vaccines being held in the EU ‘may have been a joke’ Senior Tories have cast doubt on Boris Johnson’s claim that he seriously considered inv...
UK considered ‘aquatic raid’ on Netherlands to seize Covid vaccine: Boris
In his memoir, former UK PM Boris Johnson disclosed that during the pandemic, he explored an aquatic raid on a Dutch warehouse to obtain AstraZeneca vaccines. The plan was discussed with military lead...
AstraZeneca's Top-Selling Cancer Drug Tagrisso Receives FDA Green Light For Another Lung Cancer Indication
Thursday, the FDA approved AstraZeneca Plc’s (NASDAQ: AZN) Tagrisso (osimertinib) for adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung...